NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Halozyme Therapeutics, Inc. (HALO), Capricor Therapeutics, Inc. (CAPR), Appian Corporation (APPN), Yext Inc. (YEXT), Agile Therapeutics, Inc. (AGRX), and Corbus Pharmaceuticals Holdings, Inc. (CRBP), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
HALO DOWNLOAD: http://Fundamental-Markets.com/register/?so=HALO
CAPR DOWNLOAD: http://Fundamental-Markets.com/register/?so=CAPR
APPN DOWNLOAD: http://Fundamental-Markets.com/register/?so=APPN
YEXT DOWNLOAD: http://Fundamental-Markets.com/register/?so=YEXT
AGRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=AGRX
CRBP DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRBP
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Halozyme Therapeutics, Inc. (HALO), Capricor Therapeutics, Inc. (CAPR), Appian Corporation (APPN), Yext Inc. (YEXT), Agile Therapeutics, Inc. (AGRX), and Corbus Pharmaceuticals Holdings, Inc. (CRBP) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed December 24th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
HALOZYME THERAPEUTICS, INC. (HALO) REPORT OVERVIEW
Halozyme Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Halozyme Therapeutics reported revenue of $25.56MM vs $63.73MM (down 59.90%) and analysts estimated basic earnings per share -$0.19 vs $0.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Halozyme Therapeutics reported revenue of $316.61MM vs $146.69MM (up 115.84%) and analysts estimated basic earnings per share $0.46 vs -$0.81. Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.85. The estimated EPS forecast for the next fiscal year is -$0.64 and is expected to report on February 19th, 2019.
To read the full Halozyme Therapeutics, Inc. (HALO) report, download it here: http://Fundamental-Markets.com/register/?so=HALO
-----------------------------------------
CAPRICOR THERAPEUTICS, INC. (CAPR) REPORT OVERVIEW
Capricor Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Capricor Therapeutics reported revenue of $0.22MM vs $0.31MM (down 30.04%) and analysts estimated basic earnings per share -$0.14 vs -$0.12. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Capricor Therapeutics reported revenue of $2.67MM vs $4.00MM (down 33.32%) and analysts estimated basic earnings per share $0.10 vs -$1.01. Analysts expect earnings to be released on March 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.50 and is expected to report on March 13th, 2019.
To read the full Capricor Therapeutics, Inc. (CAPR) report, download it here: http://Fundamental-Markets.com/register/?so=CAPR
-----------------------------------------
APPIAN CORPORATION (APPN) REPORT OVERVIEW
Appian's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Appian reported revenue of $54.95MM vs $44.65MM (up 23.07%) and analysts estimated basic earnings per share -$0.24 vs -$0.10. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Appian reported revenue of $176.74MM vs $132.92MM (up 32.96%) and analysts estimated basic earnings per share -$0.63 vs -$0.39. Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.58 and is expected to report on February 28th, 2019.
To read the full Appian Corporation (APPN) report, download it here: http://Fundamental-Markets.com/register/?so=APPN
-----------------------------------------
YEXT INC. (YEXT) REPORT OVERVIEW
Yext's Recent Financial Performance
For the three months ended October 31st, 2018 vs October 31st, 2017, Yext reported revenue of $58.74MM vs $44.33MM (up 32.50%) and basic earnings per share -$0.25 vs -$0.19. For the twelve months ended January 31st, 2018 vs January 31st, 2017, Yext reported revenue of $170.20MM vs $124.26MM (up 36.97%) and analysts estimated basic earnings per share -$0.85 vs -$1.39. Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was -$0.18. The estimated EPS forecast for the next fiscal year is -$0.81 and is expected to report on March 14th, 2019.
To read the full Yext Inc. (YEXT) report, download it here: http://Fundamental-Markets.com/register/?so=YEXT
-----------------------------------------
AGILE THERAPEUTICS, INC. (AGRX) REPORT OVERVIEW
Agile Therapeutics' Recent Financial Performance
Analysts expect earnings to be released on March 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.18. The estimated EPS forecast for the next fiscal year is -$0.58 and is expected to report on March 11th, 2019.
To read the full Agile Therapeutics, Inc. (AGRX) report, download it here: http://Fundamental-Markets.com/register/?so=AGRX
-----------------------------------------
CORBUS PHARMACEUTICALS HOLDINGS, INC. (CRBP) REPORT OVERVIEW
Corbus Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Corbus Pharmaceuticals reported revenue of $1.09MM vs $0.80MM (up 37.00%) and analysts estimated basic earnings per share -$0.26 vs -$0.14. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Corbus Pharmaceuticals reported revenue of $2.44MM vs $1.91MM (up 27.67%) and analysts estimated basic earnings per share -$0.65 vs -$0.49. Analysts expect earnings to be released on March 11th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.20. The estimated EPS forecast for the next fiscal year is -$0.94 and is expected to report on March 11th, 2019.
To read the full Corbus Pharmaceuticals Holdings, Inc. (CRBP) report, download it here: http://Fundamental-Markets.com/register/?so=CRBP
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.